Sogroya Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - vöxtur - hinsveiflur og heilahimnubólur og hliðstæður - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Abiraterone Krka Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateron asetat - blöðruhálskirtli - innkirtla meðferð - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Orgovyx Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

orgovyx

accord healthcare s.l.u. - relugolix - blöðruhálskirtli - innkirtla meðferð - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.